Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1948-1953

  Zalcberg, J ^a   Millward, M ^a   Bishop, J ^a   McKeage, M ^a   Zimet, A ^a   Toner, G ^a   Friedlander, M ^a   Barter, C ^a   Rischin, D ^a   Loret, C ^a   James, R ^a   Bougan, N ^a   Berille, J ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; MAGNESIUM; ONDANSETRON; PROMETHAZINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DYSPNEA; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031804718     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1948     Document Type: Article

References (14)

1. Cancer statistics, 1992. Ca Cancer J Clin 42:19-38, 1992
2. Ringel I, Horwitz SB: Studies with Taxotere (RP 56976): A semisynthetic analog of Taxol. J Natl Cancer Inst 83:288-291, 1991
3. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
4. Fossella FV, Lee JS, Berille J, et al: Summary of phase II data of docetaxel (Taxotere), an active agent in the first and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 22:22-29, 1995 (suppl 4)
5. Joss RA, Cavalli F, Goldhirsch A: New agents in non-small cell lung cancer. Cancer Treat Rev 11:205-236, 1984
6. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
7. Millward MJ, Zalcberg J, Bishop JF, et al: Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 15:750-758, 1997
8. Klastersky J, Sculier JP: Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. European Lung Cancer Working Party. Lung Cancer 12:S117-S125, 1995 (suppl 12)
9. Steward WP, Dunlop DJ, Cameron C, et al: Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. Semin Oncol 23:43-47, 1996 (suppl 10)
10. Le Chevalier T, Pujol JL, Douillard JY, et al: A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: An expanded analysis. Semin Oncol 21:28-33, 1994 (suppl 10)
11. Gonzales Baron M, Feliu J, Espinosa E, et al: Comparison of two chemotherapeutic regimens - mitomycin + vindesine + cisplatin vs. mitomycin + ifosfamide + cisplatin - in advanced non-small-cell lung cancer. Ann Oncol 5:323-327, 1994
12. Bunn PA Jr: The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin Oncol 23:18-25, 1996 (suppl 16)
13. Cole JT, Gralla RJ, Marques CB, et al: Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer. Proc Am Soc Clin Oncol 14:357, 1995 (abstr 1087)
14. Le Chevalier T, Belli L, Monnier A, et al: Phase II study of docetaxel (Taxotere) and cisplatin in advanced non small cell lung cancer (NSCLC): An interim analysis. Proc Am Soc Clin Oncol 14:350, 1995 (abstr 1059)